Cargando…

Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19

The novel coronavirus 2019 (COVID-19) infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global pandemic that requires a multi-faceted approach to tackle this unprecedent health crisis. Therapeutics to treat COVID-19 are an integral part of any such management stra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fisk, Marie, Althage, Magnus, Moosmang, Sven, Greasley, Peter J., Cope, Andrew P., Jayne, David RW., Galloway, James, Hall, Frances, Wilkinson, Ian B., Ambery, Philip, Cheriyan, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd. 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084922/ https://www.ncbi.nlm.nih.gov/pubmed/33933611 http://dx.doi.org/10.1016/j.pupt.2021.102035

Ejemplares similares

Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19
por: Abraham, George R., et al.
Publicado: (2022)

The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan
por: Veenit, Vandana, et al.
Publicado: (2023)

Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial
por: Kulkarni, Spoorthy, et al.
Publicado: (2020)

muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial
por: Lu, Ing Ni, et al.
Publicado: (2020)

Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial
por: Hall, Frances C, et al.
Publicado: (2023)

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
por: Dekkers, Claire C. J., et al.
Publicado: (2019)

Plasma Pro‐Endothelin‐1 Peptide Concentrations Rise in Chronic Kidney Disease and Following Selective Endothelin A Receptor Antagonism
por: Dhaun, Neeraj, et al.
Publicado: (2015)

Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension
por: Heidari Nejad, Sayeh, et al.
Publicado: (2023)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
por: Armour, Sarah L., et al.
Publicado: (2022)

Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET (A) receptor antagonism
por: Asham, E, et al.
Publicado: (2001)

Endothelin Receptor A Antagonism Attenuates Renal Medullary Blood Flow Impairment in Endotoxemic Pigs
por: Fenhammar, Johan, et al.
Publicado: (2011)

Serial troponin measurements to monitor risk and response to endothelin A antagonism in chronic kidney disease
por: Anand, Atul, et al.
Publicado: (2020)

Role of sodium‐glucose transporters in glucose uptake of the intestine and kidney
por: Harada, Norio, et al.
Publicado: (2012)

The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure
por: BJORNSTAD, PETTER, et al.
Publicado: (2021)

Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism
por: Sourdon, Joevin, et al.
Publicado: (2017)

Anti-Hypotensive Treatment and Endothelin Blockade Synergistically Antagonize Exercise Fatigue in Rats under Simulated High Altitude
por: Radiloff, Daniel, et al.
Publicado: (2014)

A metabolomics‐based molecular pathway analysis of how the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes
por: Mulder, Skander, et al.
Publicado: (2020)

Sodium-dependent glucose transporter 1 and glucose transporter 2 mediate intestinal transport of quercetrin in Caco-2 cells
por: Li, Suyun, et al.
Publicado: (2020)

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
por: D'Onofrio, Nunzia, et al.
Publicado: (2021)

Mitogen-stimulated glucose transport in thymocytes. Possible role of Ca++ and antagonism by adenosine 3':5'-monophosphate
Publicado: (1977)

Endothelin
por: Davenport, Anthony P., et al.
Publicado: (2016)

Comparison of analysis approaches for multi-level vascular imaging data
por: Forman, Julia, et al.
Publicado: (2015)

Endothelin and Endothelin Antagonists in Chronic Kidney Disease
por: Kohan, Donald E., et al.
Publicado: (2014)

Medication counselling with sodium glucose transporter 2 inhibitor therapy
por: Kalra, Sanjay, et al.
Publicado: (2014)

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
por: Kalra, Sanjay, et al.
Publicado: (2015)

Harms and benefits of sodium-glucose co-transporter 2 inhibitors
por: Chesterman, Thomas, et al.
Publicado: (2020)

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
por: Erythropoulou-Kaltsidou, Anastasia, et al.
Publicado: (2019)

The expression and survival significance of sodium glucose transporters in pancreatic cancer
por: Du, Jiali, et al.
Publicado: (2022)

Sodium-glucose co-transporter 2 inhibitors beyond diabetes
por: Williams, Dimity L, et al.
Publicado: (2022)

Sodium glucose co-transport 2 inhibitors for gout treatment
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2022)

Nociceptive tolerance is improved by bradykinin receptor B1 antagonism and joint morphology is protected by both endothelin type A and bradykinin receptor B1 antagonism in a surgical model of osteoarthritis
por: Kaufman, Gabriel N, et al.
Publicado: (2011)

Antagonism of the Sodium-Potassium ATPase Impairs Chikungunya Virus Infection
por: Ashbrook, Alison W., et al.
Publicado: (2016)

Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19
por: Sanghavi, Devang K., et al.
Publicado: (2021)

Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice
por: Vergara, Ander, et al.
Publicado: (2022)

Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
por: Zanoli, L., et al.
Publicado: (2015)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
por: Wu, Victor Chien-Chia, et al.
Publicado: (2021)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Jing, Yuling, et al.
Publicado: (2022)

Endothelin-1 Reduces Glucose Uptake in Human Skeletal Muscle In Vivo and In Vitro
por: Shemyakin, Alexey, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_buvbuvnmp9bi7brev3hqg6luvu